AbbVie Reports Q4 EPS of $2.16, Beats Expectations

AbbVie's Q4 earnings report exceeded expectations, with the company announcing an EPS of $2.16. This marks a significant achievement for the pharmaceutical giant.

AbbVie's financial performance in Q4 was impressive, with the company's revenue reaching new heights. The pharmaceutical giant's success can be attributed to its diverse portfolio of products, which includes Humira, a widely used treatment for autoimmune diseases.

The EPS of $2.16 is a notable figure, surpassing the market's expectations. This achievement is a testament to AbbVie's ability to deliver strong financial results.

Additional reading: Financial Reporting Accountant

AbbVie's Q4 2024 revenue came in at $15.1 billion, exceeding analyst estimates by 5.6% year-on-year growth.

The company's operating margin took a hit, with a negative margin of -9.9% due to non-recurring impairment and amortization charges. This is a significant decline from the 22.3% operating margin in the same quarter last year.

AbbVie's adjusted EPS for Q4 2024 was $2.16, missing analyst expectations by 4.3%. This marks a decline from the $2.80 reported in the same quarter last year.

The company's adjusted EPS guidance for 2025 is $12.22 at the midpoint, beating analyst estimates by 0.8%. This suggests a slight improvement in profitability for the upcoming year.

AbbVie's market capitalization stands at $310.4 billion, a significant figure that reflects the company's market value.

See what others are reading: Abbvie Market Cap

AbbVie's guidance for full-year 2025 adjusted EPS is $12.12 to $12.32, with the low end of that range higher than the average analyst estimate.

AbbVie president Robert A. Michael is optimistic about the company's future, stating that they are entering 2025 with significant momentum and expect net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity.

Investors seem to agree, as the company's guidance was a major highlight of their Q4 results.

AbbVie's revenue surprise rate is a key metric to understand its financial performance. The company's Q4 earnings snapshot showed a 1.9% beat on Wall Street's estimates.

The revenue surprise rate is calculated by comparing the company's actual revenue to the expected revenue. In AbbVie's case, its $15.1 billion revenue exceeded expectations by 1.9%. This indicates a positive surprise, which can be a good sign for investors.

To put this into perspective, the average healthcare company typically sees revenue growth of around 8% per year. However, AbbVie's recent revenue growth has been impacted by foreign exchange rates, which have been a headwind for the company.

Here's a breakdown of AbbVie's revenue growth over the last two years:

As you can see, AbbVie's revenue growth has been improving over time, with a 5.6% growth rate last year. This is a positive trend that investors should take note of.

AbbVie is a Dividend King with a high forward dividend yield of 3.5%.

The company's stock is reasonably valued with a forward earnings multiple of 14.6, which suggests it's not overpriced.

Analysts' consensus rating for AbbVie is Moderate Buy based on 15 Buy and six Hold ratings over the past three months.

The average price target for AbbVie stock is $201.37, representing a potential 14.64% upside.

AbbVie's guidance for 2025 adjusted EPS is $12.12 to $12.32, with the low end of the range higher than the average analyst estimate.

The company's president, Robert A. Michael, is optimistic about AbbVie's momentum, expecting net revenues to exceed their previous peak in just the second full year following the U.S. Humira loss of exclusivity.

Investors especially liked AbbVie's guidance, which suggests the company is on track for strong growth.

On a similar theme: Abbv Stock Dividend History

Abbvie is a biopharmaceutical company that has been around for over a century. It was founded in 2013 as a result of the separation of Abbott Laboratories into two independent companies.

Abbvie's main focus is on developing and commercializing innovative therapies for various diseases, including immune-mediated diseases, oncology, and virology.

The company has a diverse portfolio of products, including Humira, which is a top-selling medication for autoimmune diseases.

Abbvie has a global presence with operations in over 40 countries worldwide.

AbbVie reported Q4 EPS of $2.16, which is a 4.3% miss from analyst expectations. This may seem like a setback, but let's take a closer look at the bigger picture.

Revenue for the quarter came in at $15.1 billion, which is a 5.6% year-on-year growth and a 1.9% beat from analyst estimates. That's a significant increase!

The company's operating margin, however, took a hit, coming in at -9.9%. This is a stark contrast to the same quarter last year, when the margin was 22.3%. The negative margin was caused by non-recurring impairment and amortization charges.

AbbVie's constant currency revenue rose 6.1% year-on-year, which is a notable improvement from the -5.4% in the same quarter last year.

Here are some key highlights from AbbVie's Q4 results:

Overall, AbbVie's Q4 results show a mixed picture, but the company's growth platform delivered outstanding results, and its pipeline is advancing with key regulatory approvals and promising data.